KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Equity (2016 - 2025)

Novavax has reported Return on Equity over the past 15 years, most recently at 3.1% for Q4 2025.

  • Quarterly results put Return on Equity at 3.1% for Q4 2025, down 342.0% from a year ago — trailing twelve months through Dec 2025 was 3.1% (down 342.0% YoY), and the annual figure for FY2025 was 1.17%, down 145.0%.
  • Return on Equity for Q4 2025 was 3.1% at Novavax, up from 5.74% in the prior quarter.
  • Over the last five years, Return on Equity for NVAX hit a ceiling of 9.2% in Q1 2022 and a floor of 31.8% in Q4 2021.
  • Median Return on Equity over the past 5 years was 0.48% (2024), compared with a mean of 2.04%.
  • Biggest five-year swings in Return on Equity: tumbled -3066bps in 2021 and later skyrocketed 3290bps in 2022.
  • Novavax's Return on Equity stood at 31.8% in 2021, then surged by 103bps to 1.1% in 2022, then dropped by -29bps to 0.78% in 2023, then plummeted by -58bps to 0.33% in 2024, then crashed by -1050bps to 3.1% in 2025.
  • The last three reported values for Return on Equity were 3.1% (Q4 2025), 5.74% (Q3 2025), and 22.24% (Q2 2025) per Business Quant data.